Sam Brusco, Associate Editor01.18.24
Abbott has gained expanded MRI labeling approval from the U.S .Food and Drug Administration (FDA) for its Proclaim dorsal root ganglion (DRG) stimulation. Patients implanted with Proclaim DRG can now receive full-body MRI scans.
Proclaim DRG provides targeted relief for patients suffering from complex regional pain syndrome (CRPS) types I and II of the lower limbs by stimulating the DRG, clusters of nerve cells found along the spine. Abbott said that four out of five people who receive the therapy experience significant pain relief and improved quality of life.
MRIs can be used to help assess the progression of CRPS. With the expanded MRI labeling, full-body scans can be made for new and existing patients. Safe scanning is enabled of any body part with standard MRI scanners, according to Abbott. There is also compatibility with 50cm SlimTip DRG leads.
"The ability to do full-body MRI scans with the Proclaim DRG neurostimulation system means that, as physicians, we can ensure that people are receiving the care they need in a timely manner because they aren’t having to search for a facility that can accommodate special MRI settings for their device," said Timothy Deer, M.D., DABPM, president and CEO of the Spine and Nerve Centers of the Virginias. "With these expanded MRI capabilities, we no longer need to sacrifice superior pain relief and quality of life outcomes in exchange for MRI needs."
"As we continue to work holistically across chronic pain care, we’re excited to see this new MRI expanded indication for our proprietary and unique Dorsal Root Ganglion Stimulation therapy become another valuable tool in the hands of treating physicians helping people get back to living a life on their terms," added Pedro Malha, Abbott’s VP of neuromodulation.
Learn more about different technologies used to treat chronic pain here!
Proclaim DRG provides targeted relief for patients suffering from complex regional pain syndrome (CRPS) types I and II of the lower limbs by stimulating the DRG, clusters of nerve cells found along the spine. Abbott said that four out of five people who receive the therapy experience significant pain relief and improved quality of life.
MRIs can be used to help assess the progression of CRPS. With the expanded MRI labeling, full-body scans can be made for new and existing patients. Safe scanning is enabled of any body part with standard MRI scanners, according to Abbott. There is also compatibility with 50cm SlimTip DRG leads.
"The ability to do full-body MRI scans with the Proclaim DRG neurostimulation system means that, as physicians, we can ensure that people are receiving the care they need in a timely manner because they aren’t having to search for a facility that can accommodate special MRI settings for their device," said Timothy Deer, M.D., DABPM, president and CEO of the Spine and Nerve Centers of the Virginias. "With these expanded MRI capabilities, we no longer need to sacrifice superior pain relief and quality of life outcomes in exchange for MRI needs."
"As we continue to work holistically across chronic pain care, we’re excited to see this new MRI expanded indication for our proprietary and unique Dorsal Root Ganglion Stimulation therapy become another valuable tool in the hands of treating physicians helping people get back to living a life on their terms," added Pedro Malha, Abbott’s VP of neuromodulation.
Learn more about different technologies used to treat chronic pain here!